Market Dynamics of Myasthenia Gravis: Growth, Challenges, and Emerging Therapies

Myasthenia Gravis (MG) is an autoimmune disorder where the immune system erroneously targets the body’s own tissues, particularly disrupting communication between the nerves and muscles at the neuromuscular junction. The primary autoantibodies responsible for MG target the nicotinic acetylcholine receptor (AChR), followed by muscle-specific kinase (MuSK) and lipoprotein receptor-related protein 4 (LRP4). This disorder results in fluctuating, painless muscle weakness that worsens with physical exertion. Early symptoms typically include weakness in the eye muscles, causing drooping eyelids (ptosis) and double vision (diplopia). In some cases, the condition may also begin with weakness in the limbs or throat.

For more details on the trends in Myasthenia Gravis, check out DelveInsight’s Myasthenia Gravis Market Infographics.

Epidemiological Insights on Myasthenia Gravis

From 2020 to 2034, the epidemiological analysis across the seven major markets (7MM) covers key segments, including:

• Total number of diagnosed prevalent MG cases

• Diagnosed prevalence by gender

• Diagnosed prevalence by age group

• Prevalence according to MGFA classification

• Generalized MG cases categorized by antibody type

Epidemiological Highlights

In 2023, the U.S. had approximately 129,000 individuals diagnosed with Myasthenia Gravis, with this number projected to rise steadily through 2034. In the EU4 countries (France, Germany, Italy, Spain) and the UK, an estimated 125,000 people had been diagnosed, with case numbers expected to increase in the forecast period. Germany reported the highest prevalence in the EU4 and UK, with 39,000 cases, followed by the UK and France. Spain had the fewest cases. Japan's diagnosed cases were around 32,000 in 2023, with significant growth anticipated. The highest prevalence was seen in individuals aged 65 and older, while the lowest occurred among children and adolescents (ages 0–17).

Myasthenia Gravis Market Overview

In 2023, the Myasthenia Gravis market across the 7MM reached approximately USD 5 billion.

Key drivers of the market include the increasing prevalence of MG and an aging population, which is expected to drive demand for treatments. As more companies enter the MG treatment market, competition and innovation are also contributing to market growth. However, challenges such as limited treatment options for specific MG subtypes may slow down this growth. Additionally, the high costs of novel therapies, particularly biologics, may hinder accessibility for some patients.

For a more comprehensive understanding of the Myasthenia Gravis market, refer to DelveInsight’s Myasthenia Gravis Market Report.

Emerging Therapies for Myasthenia Gravis

There are several promising therapies in development for Myasthenia Gravis, such as:

• UPLIZNA

• Nipocalimab

• ENSPRYNG

• Batoclimab

• Gefurulimab

• Pozelimab + Cemdisiran

• KYV-101

These drugs are showing promise in the treatment of MG, offering hope for better patient outcomes.

Key Companies in the Myasthenia Gravis Market

Several major pharmaceutical and biotech companies are leading the way in MG treatment development, including:

• Horizon Therapeutics

• Amgen

• Janssen R&D

• Hoffmann-La Roche

• Immunovant Sciences

• Alexion (AstraZeneca Rare Disease)

• Regeneron Pharmaceuticals

• Kyverna Therapeutics

• Cartesian Therapeutics

• Dianthus Therapeutics

• Takeda

• COUR Pharmaceuticals

• And many others.

These companies are actively involved in advancing the treatment options for MG through ongoing research and development.

To gain more insights into the Myasthenia Gravis market dynamics, visit DelveInsight’s Myasthenia Gravis Market Infographics.